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Introduction
The introduction of anti-tumor necrosis factor-α (anti-TNF) 
has lead to improved remission rates and disease control in 
patients with Crohns disease [1]. The first available anti-TNF drug, 
infliximab, is still widely used to induce remission [2]. Although 
infliximab is relatively safe, it may increase risk of opportunistic 
infections [3], the risk of cancer [4] and treatment poses a burden 
to the health care system. Therefore, the potential for stratifying 
patients into those in need for long-term treatment and those 
who potentially could do with initial treatment needs further 
investigation.  
The European Guidelines recommend maintenance therapy 
in all patients when remission is achieved by induction therapy 
[5]. The American Gastroenterological Association Guidelines 
also recommend maintenance therapy but focus on possible 
opportunistic infections such as tuberculosis or fungal infections 
as possible issues which can weigh towards termination of the 
therapy. Also in these guidelines, it is mentioned that long-term 
use of biologics are expensive [6]. According to the Danish national 
guidelines, treatment can be stopped if induction therapy induces 
remission [7]. Evidence behind the varying recommendations is 
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Abstract 
Background/Aims: The need for maintenance therapy with infliximab after remission in patients with benign Crohn’s disease remains to be 
studied. Our hypothesis was that patients with benign Crohn’s disease did not need maintenance therapy after induction therapy if remission 
had been achieved.
Materials and methods: In a population-based regional Danish cohort of patients with Crohn’s disease, we identified those initiating 
infliximab therapy from 2010 to 2016 (n=312). As per protocol, those with predictors of severe prognosis (i.e. perianal -, fistulizing -, or extensive 
disease, young age, or previous surgery) continued on maintenance treatment as did those who had not obtained remission. We studied the 
benign cases with remission and no maintenance therapy.
Results: Of the 312 Crohn’s disease patients exposed to infliximab induction therapy, 174 obtained remission, and of these 56 (31.5%) were 
judged to be benign cases and were not scheduled for further infliximab treatment. Thirty of these patients (53.6%) were still in remission after 
6 months, 19 patients (33.9%) after one year, and only 16 (28.6%) after two years. Patients who relapsed within 6 months had higher CRP levels 
at initiation of infliximab therapy than individuals who did not relapse within 6 months (13.7 mg/L vs. 4.6 mg/L; p=0.002). 
Conclusion: This study shows high relapse rates after infliximab induction therapy in benign Crohn’s disease. Interestingly, Harvey Bradshaw 
Index and fecal calprotectin did not predict relapse, whereas high initial CRP levels did. 
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limited, and real-life studies on remission rates after induction 
therapy in specific subgroups of patients from unselected 
population-based cohorts are lacking. 
Randomized controlled studies, where patients are put on 
placebo after induction therapy have demonstrated that about 
20% obtain long-term remission after mere induction therapy 
[8,9]. Furthermore several studies have demonstrated, that 
nearly all patients regain effect of the drug, when reintroduced 
in patients who relapse after a drug holyday [9]. The aim of the 
present study was to conduct a real-life population-based cohort 
study on the rate of relapse in patients with benign Crohn’s disease 
after exposure to anti-TNF induction treatment only, and to assess 
the impact of potential predictors for relapse. 
Materials and Methods
The study population was drawn from a population-based 
cohort of all patients with Crohn’s disease (n = ~1,200) from the 
North Denmark Region (583,000 inhabitants) [10]. All patients 
with Crohn’s disease treated with infliximab during 2010-2016 
were identified, using the database “GASTROBIO”. Patients 
receiving biologic treatment for inflammatory bowel disease have 
been registered systematically in this web-based registry, which 
was established for both research purposes and for optimization 
of clinical management [11]. Patients with disease characteristics 
indicating a possible severe prognosis (i.e. perianal -, fistulizing -, 
or extensive disease, young age (<15 years), or previous surgery, 
were all put on maintenance treatment and were excluded from 
this study. Patients with disease characteristics indicating a more 
benign prognosis, and who obtained remission after induction 
therapy with infliximab were considered for this study (Figure 
1). Remission was evaluated clinically and defined as fecal 
calprotectin below 200 mg/kg and a HBI below 5. 
Figure 1: Flow-chart of infliximab treated patients from a population-based Crohn’s disease cohort 
Time to relapse
Time to relapse was measured as the difference between the 
dates of the third and fourth treatment. Early relapse was defined 
as retreatment within 6 months. 
Concomitant medication and markers of disease
Use of concomitant treatment with azathioprine (AZA) or 
6-mercaptopurine (6-MP) was registered and evaluated as one 
group, immunomodulators (IMM). Likewise, fecal calprotectin, 
C-reactive protein (CRP) and Harvey Bradshaw Index (HBI) was 
recorded in GASTROBIO at time of treatment initiation and at 
third infusion. CRP levels above 8 mg/L, fecal calprotectin above 
200 mg/kg, and HBI above 5 were considered increased according 
to local laboratory standards. 
Statistical analyses
Continuous variables were described using mean and 
standard deviation, and categorical variables were described with 
total numbers and percentages. Two-sided tests were applied 
with corresponding p-values for all statistical analyses, using a 
significance level of 5%. To assess differences between patients 
with or without retreatment regarding age at diagnosis, age at 
prescription, weight, and height, two-sided t-tests were performed. 
For the categorical variable “smoking”, the difference between the 
early and late/no retreatment groups was assessed using chi-
square test. Potential associations between disease markers (CRP, 
fecal calprotectin, and HBI) and disease relapse were tested with 
a t-test. CRP was further plotted as a dot plot of means. The log 
transformation was used to obtain normal distributed data and 
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therefore the geometric means and coefficient of variation were 
reported.
Time to retreatment was illustrated by Kaplan-Meyer curves 
overall as well as according to CRP below/above 8 at treatment 
initiation, IMM/no IMM, using the log rank test for comparison. 
To further qualify time to retreatment analyses in the two CRP 
groups, as well as concomitant IMM treatment, Cox regression 
analysis was performed, and results were expressed as hazard 
ratios (HRs) with 95% CIs. Analyses were performed using Stata 
(Stata/IC 12.1 for Windows, www.stata.com).
Ethical considerations
The study was approved by the Danish Board of Health (3-
3013-720/1) and the Danish Data Protection Agency (2008-58-
0028). 
Results
From 2010 to 2016, 312 patients with Crohn’s disease 
initiated infliximab therapy and of these, 70 who obtained 
remission, had disease characteristics indicating a possible severe 
prognosis (i.e. extensive disease, perianal location, previous 
surgery, fistulizing disease, young age (<15) at debut) and were 
all put on maintenance treatment. One hundred and four patients 
who obtained remission had disease characteristics indicating 
a more benign prognosis (Figure 1). Of these 56 patients 
discontinued infliximab after induction (‘induction only’). The 
remaining 48 patients continued with maintenance therapy 
based on an individual clinical assessment. Clinical characteristics 
are shown in Table 1. Thirty-two patients in the ‘induction only’ 
group (57.1%) and 36 patients (51.4%) in the maintenance group 
were females (p=0.59). The mean age at diagnosis was 26.8 years 
(range 15 to 52 years) in the ‘induction only’ group and 28.1 
(range 8 to 63 years) in the maintenance group. Age at diagnosis 
and at prescription were comparable between the two groups 
(p=0.55 and 0.34). Twenty-two patients (40%) in the ‘induction 
only’ group versus 17 patients (25.4%) in the maintenance group 
were smokers (p=0.12). 
Table 1: Characteristics of study cohort of infliximab treated patients with Crohn’s disease receiving either induction therapy alone or maintenance 
therapy.
Induction Therapy Maintenance Therapy P-Value
N 56 (100%) 70 (100%)
Gender
Female 32 (57.1%) 36 (51.4%) (p=0.59)
Age at diagnosis, N 56 70
Mean (Std) 26.8 (9.7) 28.1 (13.7) (p=0.55)
Age at prescription, N 56 70
Mean (Std) 32.5 (12.9) 34.9 (14.7) (p=0.34)
Weight (kg), N 43 52
Mean (Std) 71.2 (16.2) 72.6 (22.5)
Height (cm), N 53 67
Mean (Std) 173.6 (8.8) 173.3 (8.7)
Smoking habits at diagnosis, N 55 67
Yes 22 (40.0%) 17 (25.4) (p=0.12)
Previous 10 (18.2%) 14 (20.9)
Never 21 (38.2%) 35 (52.2)
Unknown 2 (3.6%) 1 (1.5)




Of the 56 patients with clinically judged benign Crohn’s 
disease receiving induction therapy only, 30 (53.6%) were still 
in remission after 6 months, whereas 28.6% had sustained 
remission after 2 years (Figure 2). Table 2 shows patients with 
need for early retreatment vs. patients with need for no or only 
later retreatment. There was no difference between these two 
groups regarding age at diagnosis (mean difference 1.8 years; 
95% CI, -3.5 to 7.0; p = 0.50), age at infliximab prescription 
(mean difference 2.0 years; 95% CI, -4.9 to 9.0; p = 0.55), weight 
(mean difference 3.4 kilos; 95% CI, -6.8 to 13.5; p = 0.50), height 
(mean difference 3.5 centimeters; 95% CI, -1.3 to 8.4; p = 0.15), 
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or smoking habits (p = 0.91). Also, regression analyses revealed 
no difference in time to retreatment between the patients with 
or without concomitant immunomodulator treatment at the third 
infliximab dose (HR 0.79; 95% CI, 0.44 to 1.44; p = 0.48). 
Table 2:  Characteristics of Crohn’s disease patients in need or no need for early retreatment after infliximab induction therapy alone.
N (%) Early Retreatment Late/No Retreatment P-Value
26 (46.4%) 30 (53.6%)
Gender
Female 14 (53.8%) 18 (60%)
Age at diagnosis, N 26 30
Mean (Std) 27.8 (10.5) 26 (9.1) (p=0.50)
Age at prescription, N 26 30
Mean (Std) 33.6 (13.7) 31.5 (12.3) (p=0.55)
Weight (kg), N 19 24
Mean (Std) 73.1 (17.1) 69.7 (15.7) (p= 0.50)
Height (cm), N 24 29
Mean (Std) 175.6 (9.4) 172.1 (8.2) (p=0.15)
Smoking habits at diagnosis, N 29 26




Immunomodulator at 3rd dose infliximab
Yes 12 19 (p=0.20)
No 14 11
Figure 2: Time from planned termination of infliximab induction therapy to need for retreatment in a population-based Crohn’s disease 
cohort.
Predictors for sustained remission
We assessed impact of HBI, fecal calprotectin, and CRP on 
prediction of sustained remission after induction therapy in 
patients with benign Crohn’s disease. There was no difference in 
HBI at first (p=0.67) or third dose (p=0.94) between patients who 
relapsed (i.e. needed early retreatment) after induction therapy 
alone and patients who had sustained remission. Likewise, there 
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was no difference in fecal calprotectin at first (p=0.86) or third 
dose (p=0.78) between patients who did or did not relapse after 
induction therapy alone. However, a low CRP at initiation of therapy 
was a statistically significant predictor of sustained remission vs. 
(relapse 13.7 mg/L vs. no relapse: 4.6 mg/L; p=0.002) (Figures 3 
& 4). On the other hand, CRP at third dose was not a predictor of 
prognosis (p=0.53).
Figure 3:  C-reactive protein (CRP) at initiation of infliximab induction therapy according to need for early retreatment in a population-based 
Crohn’s disease cohort.
Figure 4: Proportion of patients needing retreatment with infliximab according to time since end of induction therapy in a population-based 
Crohn’s disease cohort. 
Effect of re-treatment
Of the 26 patients in the early retreatment group, 24 patients 
(92.3%) regained response after re-treatment with IFX. One 
patient changed to another biological agent and one underwent 
surgery. No allergic reactions were reported.
Discussion
In the present real-life population-based cohort study of 312 
patients receiving infliximab treatment in Northern Jutland during 
years 2010-2016, the effect of infliximab induction therapy alone 
in patients with benign Crohn’s disease was evaluated. The present 
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study demonstrated that among these patients, approximately 
50% were in remission 6 months after end of induction therapy. 
One third were in remission after 1 year and just above one fourth 
after 2 years. Initial low CRP levels were predictive for sustained 
remission, whereas fecal calprotectin and HBI did not predict 
relapse.
Strengths and limitations
The primary strength of the present study was the real-life 
investigation of a geographically well-defined population covering 
a calendar period of 7 years. To our knowledge, this is the largest 
real-life study investigating remission after induction therapy 
alone in patients with benign Crohn’s disease. Further, all patients 
in the North Jutland region of Denmark had been treated in one 
single center with the same core group of physicians managing 
patients throughout the entire period. The study also has 
potential limitations, which need to be considered. First, changes 
in prescription patterns and management of therapy could have 
occurred during the study period. Importantly, the study did not 
cover the first decade post-marketing hence avoiding early user 
bias. Second, the number of patients receiving induction therapy 
only was, despite the lack of previous similar data, of limited 
size, which may influence power in certain sub-analyses. Lastly, 
unmeasured confounding may occur. 
Comparison with previous studies
Prior to the present study, a number of smaller and potentially 
more selected studies have reported varying results. In 2005, 
Domenech and colleagues compared induction therapy alone in 
23 patients to scheduled maintenance in 27 patients. In patients 
with luminal Crohn’s disease, who had complete response after 
induction therapy with or without maintenance with infliximab, 
two thirds maintained a sustained effect for more than two 
years [12]. However, they were almost all on concomitant 
immunomodulator therapy while this was the case for only half 
of our patients. Immunomodulator therapy has been shown to 
increase the effect of IFX which could explain this finding [13]. 
There was no significant difference in one year relapse rates 
between patients receiving induction therapy alone (relapse rate, 
22%) and patients receiving one year’s maintenance therapy 
(relapse rate, 31%). Likewise, in a comparable study with 92 
patients, Chauvin and colleagues found no difference in relapse 
rates between the induction therapy only and maintenance group 
after one year (29 vs 44%) [14]. A systematic review by Torres 
and colleagues including 32 prospective and retrospective cohort 
studies, but no unselected population-based studies concluded 
that approximately 55-60 % of patients who discontinued 
anti-TNF therapy would relapse within 2 years regardless of 
concomitant immunomodulator therapy [15]. 
Predictors for response
In the present real-life population-based unselected cohort 
study of 312 patients of whom 56 received induction therapy 
only, relapse rates were 46% after only 6 months and only 29% 
remained in remission after two years. Thus, even after careful 
clinical assessment of patients to determine whom would need 
induction therapy only, treatment appeared insufficient for half 
of the patients already within the first six months. It could be 
discussed whether other features, like for example smoking habits, 
should be part of our clinical assessment. Through examination of 
prospectively collected data on CRP, HBI, and fecal calprotectin, we 
assessed these factors as potential predictors of relapse and hence 
as potential factors for patient stratification. We found that even 
a slight elevation in CRP at initiation of therapy was a predictor 
for need for early retreatment. This is partly in accordance with 
previous studies reporting that elevated CRP levels are associated 
with an increased risk of short-term relapse [16]. It has previously 
been shown that an elevated CRP at discontinuation of therapy 
is associated with a higher risk of relapse [17]. As considered 
in this paper, some patients do not synthesize CRP despite 
active inflammation, thus potentially rendering false negative 
measurement. However, it is not surprising, that elevated CRP is 
a predictor for relapse, as these patients are likely to have active 
disease. Other studies looked at CRP after one year’s treatment or 
even after induction therapy, and it has been shown that younger 
age at diagnosis, smoking and longer disease duration as well as 
high CRP and fecal calprotectin levels were factors associated 
with higher risk of relapse after discontinuation of infliximab 
maintenance therapy [18]. In contrast to findings for CRP, we did 
not find fecal calprotectin or HBI to differ between patients who 
relapsed and patients who remained in remission after induction 
therapy only. 
Our finding of no impact of fecal calprotectin is quite 
surprising, since other studies have established an association 
between elevated fecal calprotectin levels and an increased risk of 
relapse [19]. However, we may have introduced selection bias by 
providing maintenance therapy to those with a fecal calprotectin 
level above 200 mg/kg. Real life studies assessing HBI as a marker 
of relapse are lacking. Regarding exposure to immunomodulators, 
we did not observe an impact on risk of relapse. This is in contrast 
to a retrospective observational multicenter study from 78 
Spanish centers suggesting that immunomodulator therapy at 
time of discontinuation of anti-TNF therapy was associated with a 
lower risk of relapse [20]. However, population-based studies for 
comparison are lacking.
Conclusion
In conclusion, our population-based real-life study of 
cessation of infliximab treatment after induction therapy in 
patients with benign Crohn’s disease showed sustained remission 
after two years in one fourth of patients and this subgroup may 
represent a particular disease phenotype, where inflammation 
can be controlled with infliximab induction therapy exclusively. 
We identified CRP level at initiation of therapy as a potential 
patient stratifier, whereas fecal calprotectin, HBI, and treatment 
with immunomodulators were not predictive of relapse. Our study 
underscores the need for development of algorithms that enable 
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identification of patients in whom termination of treatment after 
induction therapy can be recommended.
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